Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

July 11, 2024

Primary Completion Date

August 30, 2029

Study Completion Date

October 30, 2029

Conditions
Long Term Follow-up
Interventions
OTHER

Non-interventional

This is a rollover study

Trial Locations (18)

3004

RECRUITING

The Alfred Hospital, Melbourne

6150

NOT_YET_RECRUITING

Fiona Stanley Hospital, Murdoch

33136

NOT_YET_RECRUITING

University of Miami Miller School of Medicine, Miami

33305

RECRUITING

Chang Gung Medical Foundation Linkou, Taoyuan District

40705

RECRUITING

Taichung Veterans General Hospital, Taichung

60002

RECRUITING

Chia-Yi Christian Hospital, Chiayi City

80756

RECRUITING

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

82445

RECRUITING

E-Da Hospital, Kaohsiung City

92105

RECRUITING

Research and Education Inc., San Diego

600566

RECRUITING

Changhua Christian Hospital, Changhua

08844

RECRUITING

Infectious Disease Care, Hillsborough

Unknown

RECRUITING

Prince of Wales Hospital, Shatin

RECRUITING

Queen Mary Hospital, Hong Kong

RECRUITING

Arensia Exploratory Medicine Moldova, Chisinau

05505

NOT_YET_RECRUITING

Asan Medial Center, Seoul

CF144XW

NOT_YET_RECRUITING

University Hospital of Wales, Cardiff, Cardiff

E11FR

NOT_YET_RECRUITING

Royal London Hospital, London

SE59RS

NOT_YET_RECRUITING

King's College Hospital, London

Sponsors
All Listed Sponsors
lead

Arbutus Biopharma Corporation

INDUSTRY

NCT06277037 - Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729) | Biotech Hunter | Biotech Hunter